Subsequent to December 31, 2023, through February 29, 2024, Iterum sold 2.9 million ordinary shares under an at-the-market offering agreement, at an average price of $2.52 per share for net proceeds of $7.1 million, which has extended cash runway into 2025 based on its current operating plan. As of February 29, 2024, Iterum had approximately 16.4 million ordinary shares outstanding.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITRM:
- Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
- Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
- Iterum Therapeutics expects to resubmit oral sulopenem NDA in 1H of 2Q24
- Iterum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
- Biotech Alert: Searches spiking for these stocks today
